HBSP (USA)
-
Transition at DataCo (Spanish Version)
Cespedes, Frank V.; Knoop, Carin-IsabelCase HBS-818S06EntrepreneurshipEl fundador de una compañía de análisis de datos, Stefan Brecht, tiene varios problemas con su desarrollador de negocios clave y el jefe de marketing y ventas, Tamara Smithson. Smithson, un alquiler principios que habían sido fundamentales en la construcción de la empresa funciona como un miembro, no se atreve a delegar tareas y clientes, y, como Brecht lo ve "a menudo pone los asuntos del cliente por delante de las necesidades y procedimientos d...Starting at €8.20
-
Dr. Ing. h.c. F. Porsche AG (A): Fiel a la marca
Fear, Jeffrey; Knoop, Carin-IsabelCase HBS-707S13StrategyExamina una de las más importantes decisiones empresariales realizadas en la historia de Porsche, realizadas a principios de 1998: para construir un vehículo utilitario deportivo (SUV) - Cayenne. Después de décadas de depender de uno o dos modelos de coches deportivos y casi en quiebra y perder su independencia en 1993, Porsche tuvo que diversificar sus líneas de productos. También examina las implicaciones de marca de la internacionalización de ...Starting at €8.20
-
Novartis: el liderazgo de una empresa global
George, William W.; Palepu, Krishna G.; Knoop, Carin-IsabelCase HBS-418S09StrategyNovartis, empresa de salud más importantes del mundo, se formó en 1996 de la fusión de dos compañías farmacéuticas muy diferente, de nivel medio con sede en Suiza. El caso describe la evolución de la compañía durante los últimos 17 años, ya que se transformó en una empresa verdaderamente global, con 127.000 empleados de 153 nacionalidades en 140 países y generando $ 56,7 mil millones en 2012 ingresos y $ 9.6 mil millones en ingresos netos, por lo...Starting at €8.20
-
Novartis: Leading a Global Enterprise
George, William W.; Palepu, Krishna G.; Knoop, Carin-IsabelCase HBS-413096-ENovartis, the world's leading healthcare company, was formed in 1996 out of a merger of two very different, mid-tier Switzerland-based pharma companies. The case traces the company's evolution over the past 17 years, as it transformed into a truly global enterprise with 127,000 employees of 153 nationalities in 140 countries generating $56.7 billion in 2012 revenues and $9.6 billion in net income, making the firm one of the world's largest and mo...Starting at €8.20
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCase HBS-313069-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €8.20
-
Acibadem Healthcare Group
Herzlinger, Regina E.; Cekin, Esel; Kindred, Natalie; Yucaoglu, GamzeCase HBS-315120-EThis case focuses on Ac badem Healthcare Group's, Turkey's only premium nationwide hospital network, potential expansion strategies after it was acquired by International Healthcare Holdings Berhad (IHH) in 2011, the world's second-largest publicly listed health care group and a private hospital leader in Singapore and Malaysia. By providing perspectives on both Ac badem and IHH-Parkway-Pantai's operational models, growth aspirations, collabora...Starting at €8.20
-
UBS: hacia la empresa integrada
Lal, Rajiv; Nohria, Nitin; Knoop, Carin-IsabelCase HBS-506S34Leadership and People ManagementA finales de junio de 2005, CEO del Grupo UBS Peter Wuffli - ungido "Master of Zurich" por la prensa financiera - volvía a Zurich a partir de la firma reciente de tres días de conferencias de liderazgo senior (SLC). Tapping 600 altos directivos, esto SLC contó con un evento al aire libre en un lugar ex militar en las montañas suizas. Bajo el lema de "La comprensión, el compromiso y la confianza", equipos de 100 ejecutivos involucrados en una simu...Starting at €8.20
-
Reinventing Brainlab (B)
Herzlinger, Regina E.; Misztal, KarolCase HBS-314054-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €5.74
-
Royal DSM: From Continuous Transformation to Organic Growth
George, William W.; Knoop, Carin-Isabel; Migdal, AmramCase HBS-317063-EStrategyRoyal DSM CEO Feike Sijbesma was pondering the challenges of shifting DSM's global organization from the constant transformations of the past 100 years to creating organic growth. When Sijbesma took the helm as CEO in 2007, he further pushed and completed the company's final moves away from commodity chemicals and toward more sustainable businesses whereby DSM could create value with differentiated offerings. Sijbesma emphasized innovation and mo...Starting at €8.20
-
MorphoSys AG: The Evolution of a Biotechnology Business Model
Pisano, Gary P.; Johnson, Ryan; Knoop, Carin-IsabelCase HBS-611046-EService and Operations ManagementIn the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently, the company decided to deviate from this model, and attempt to develop its own proprietary products. The case allows analysis of "license vs. vertically integrate" business model de...Starting at €8.20